Cargando…

Exposure to escalating olaparib does not induce acquired resistance to PARPi and to other chemotherapeutic compounds in ovarian cancer cell lines

Poly (ADP-ribose) polymerase (PARP)-inhibitors (PARPi) such as olaparib and niraparib are currently used as a treatment option for BRCA-deficient tumors and also show efficacy in platinum-sensitive tumors. However, resistance to PARPi occurs in numerous patients and in particular acquired PARPi resi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fedier, André, Maggi, Nadia, Tozzi, Alessandra, Disler, Muriel, Coelho, Ricardo, Jacob, Francis, Heinzelmann-Schwarz, Viola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2022
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9170353/ https://www.ncbi.nlm.nih.gov/pubmed/35642662 http://dx.doi.org/10.3892/ijo.2022.5379

Ejemplares similares

Overlapping gene dependencies for PARP inhibitors and carboplatin response identified by functional CRISPR-Cas9 screening in ovarian cancer
por: Coelho, Ricardo, et al.
Publicado: (2022)

PARPi after PARPi in epithelial ovarian cancer
por: Essel, K.G., et al.
Publicado: (2021)

To PARPI or Not to PARPI BRCA Mutated Ovarian Cancer Following First-line Chemotherapy, That is the Question?
por: Rose, Peter G, et al.
Publicado: (2021)

Outcome in serous ovarian cancer is not associated with LATS expression
por: Montavon, Céline, et al.
Publicado: (2019)

Tumor-Associated Glycans and Their Role in Gynecological Cancers: Accelerating Translational Research by Novel High-Throughput Approaches
por: Pochechueva, Tatiana, et al.
Publicado: (2012)

Establishment and Molecular Characterization of an In Vitro Model for PARPi-Resistant Ovarian Cancer
por: Klotz, Daniel Martin, et al.
Publicado: (2023)

Ovarian cancer resistance to PARPi and platinum-containing chemotherapy
por: Summey, Rebekah, et al.
Publicado: (2022)

ABO blood groups as a prognostic factor for recurrence in ovarian and vulvar cancer
por: Montavon Sartorius, Céline, et al.
Publicado: (2018)

Expression of GBGT1 is epigenetically regulated by DNA methylation in ovarian cancer cells
por: Jacob, Francis, et al.
Publicado: (2014)

Blood Plasma-Derived Anti-Glycan Antibodies to Sialylated and Sulfated Glycans Identify Ovarian Cancer Patients
por: Pochechueva, Tatiana, et al.
Publicado: (2016)

Ovarian cancer recurrence: is the definition of platinum sensitivity modified by PARPi, bevacizumab or other intervening treatments? : a clinical perspective
por: Rose, Peter G.
Publicado: (2022)

BETting on combination to overcome PARPi resistance
por: Zhang, Youyou, et al.
Publicado: (2017)

Ovarian cancer recurrence: is the definition of platinum resistance modified by PARPi and other intervening treatments? The evolving landscape in the management of platinum-resistant ovarian cancer
por: Flynn, Michael J., et al.
Publicado: (2022)

Careful Selection of Reference Genes Is Required for Reliable Performance of RT-qPCR in Human Normal and Cancer Cell Lines
por: Jacob, Francis, et al.
Publicado: (2013)

Olaparib Combined with an ATR or Chk1 Inhibitor as a Treatment Strategy for Acquired Olaparib-Resistant BRCA1 Mutant Ovarian Cells
por: Burgess, Brian T., et al.
Publicado: (2020)

A Phase I dose‐escalation study of two cycles carboplatin‐olaparib followed by olaparib monotherapy in patients with advanced cancer
por: Geenen, Jill J. J., et al.
Publicado: (2021)

Olaparib in the management of ovarian cancer
por: Bixel, Kristin, et al.
Publicado: (2015)

Olaparib in Epithelial Ovarian Cancer
por: Anastasia, Paula J.
Publicado: (2016)

Diaphragmatic smears are not of additional benefit in the detection of peritoneal spread in gynecological cancers
por: Montavon, Celine, et al.
Publicado: (2018)

Re-treatment with PARPi in patients with recurrent epithelial ovarian cancer: A single institutional experience
por: Moubarak, Malak, et al.
Publicado: (2022)

Hematological disorders after salvage PARPi treatment for ovarian cancer: Cytogenetic and molecular defects and clinical outcomes
por: Todisco, Elisabetta, et al.
Publicado: (2022)

HRD effects on first-line adjuvant chemotherapy and PARPi maintenance therapy in Chinese ovarian cancer patients
por: Li, Lei, et al.
Publicado: (2023)

Reliable in vitro studies require appropriate ovarian cancer cell lines
por: Jacob, Francis, et al.
Publicado: (2014)

[(18)F]PARPi Imaging Is Not Affected by HPV Status In Vitro
por: Guru, Navjot, et al.
Publicado: (2021)

Fully Automated, High-Dose Radiosynthesis of [(18)F]PARPi
por: Pacelli, Anna, et al.
Publicado: (2022)

Construction of PARPi Resistance-related Competing Endogenous RNA Network
por: Kong, Lili, et al.
Publicado: (2022)

Universal Tumor DNA BRCA1/2 Testing of Ovarian Cancer: Prescreening PARPi Treatment and Genetic Predisposition
por: Vos, Janet R, et al.
Publicado: (2019)

PARPi Decreased Primary Ovarian Cancer Organoid Growth Through Early Apoptosis and Base Excision Repair Pathway
por: Cao, Qi, et al.
Publicado: (2023)

Profile of olaparib in the treatment of advanced ovarian cancer
por: Chase, Dana M, et al.
Publicado: (2016)

Epigenetic activation of MGAT3 and corresponding bisecting GlcNAc shortens the survival of cancer patients
por: Kohler, Reto S., et al.
Publicado: (2016)

Detection of isoforms and genomic alterations by high-throughput full-length single-cell RNA sequencing in ovarian cancer
por: Dondi, Arthur, et al.
Publicado: (2023)

PARPi-FL - a Fluorescent PARP1 Inhibitor for Glioblastoma Imaging
por: Irwin, Christopher P., et al.
Publicado: (2014)

Olaparib-induced pseudoporphyria in a patient with ovarian cancer
por: Clark, Abigale, et al.
Publicado: (2023)

Mutation profiles in circulating cell‐free DNA predict acquired resistance to olaparib in high‐grade serous ovarian carcinoma
por: Hu, Dianxing, et al.
Publicado: (2022)

Vibrational Spectroscopy in Urine Samples as a Medical Tool: Review and Overview on the Current State-of-the-Art
por: Vigo, Francesco, et al.
Publicado: (2022)

Olaparib treatment for BRCA-mutant ovarian cancer with leptomeningeal disease
por: Bangham, Madeleine, et al.
Publicado: (2016)

Role of Olaparib as Maintenance Treatment for Ovarian Cancer: The Evidence to Date
por: Montemorano, Lauren, et al.
Publicado: (2019)

Olaparib and advanced ovarian cancer: Summary of the past and looking into the future
por: Maiorano, Brigida Anna, et al.
Publicado: (2023)

A clinicopathological review of 33 patients with vulvar melanoma identifies c-KIT as a prognostic marker
por: HEINZELMANN-SCHWARZ, VIOLA A., et al.
Publicado: (2014)

Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events
por: Madariaga, Ainhoa, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_jepincquqar8m8sk00ubtgg3qf